Background: Prevalence of psychological disorders among individuals with diabetes is significantly higher as compared to the general population.

Aim: This study aimed to assess the prevalence and impact of psychological disorders on pharmacotherapy of diabetes patients.

Methodology: This cross-sectional study was conducted at two primary care hospitals in Pakistan from April to June 2023. The nine-item Patient Health Care Questionnaire (PHQ-9) scale was used to assess depression in the study's population, and its effects on pharmacotherapy of diabetes. Chi-square test was used to evaluate relationship between ordinal variables/categorical variables and depression whereas; Student's -test was used to assess the relationship between numerical variables with depression.

Results: A total of 320 patients were assessed, comprising 120 (37.5%) males and 200 (62.5%) females, with a mean age of 52.5 (SD±11.8) years. The average duration of diabetes is 7.0 (SD±5.4). The average PHQ-9 score was 8.3 (SD±5.5). Depression was found to be prevalent in 43.7% of the study population. Gender (female) ( 0.002), advanced age ( 0.002), lower income (p-value 0.001), education levels ( 0.001), longer duration of diabetes ( 0.001), poor diabetes control according to BSR value ( 0.001), usage of injectable insulin ( 0.005), and concomitant diseases ( 0.001) were found to be independently linked with depression. Significant association was observed between depression and treatment adherence ( 0.0025), number of missed doses (p-value 0.045), and difficulty in diabetes management ( 0.0015).

Conclusion: Our study highlights significant prevalence of depression in study population and the prevalent depression negatively impacts on treatment adherence. It also revealed that depression complicates diabetes management resulting in poor medication adherence, poor diabetes control and diabetes related complications, making diabetes control more challenging and difficult.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11416907PMC
http://dx.doi.org/10.2147/PPA.S463133DOI Listing

Publication Analysis

Top Keywords

psychological disorders
12
diabetes control
12
diabetes
11
prevalence impact
8
impact psychological
8
disorders pharmacotherapy
8
pharmacotherapy diabetes
8
depression
8
duration diabetes
8
study population
8

Similar Publications

MiRNAs and extracellular vesicles in psychiatry: Potential biomarkers, therapeutic advances, and animal models.

Eur Neuropsychopharmacol

January 2025

Institute of Biomedical Research of Barcelona (IIBB), Spanish National Research Council (CSIC), 08036 Barcelona, Spain; Systems Neuropharmacology Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Catalonia, Spain; Biomedical Research Networking Centre Consortium on Mental Health (CIBERSAM), Instituto de Salud Carlos III, 28029 Madrid, Spain. Electronic address:

View Article and Find Full Text PDF

The Aberrant Behavior Checklist (ABC) was originally developed to evaluate interventions, and is a well-established assessment tool for challenging behaviours in people with intellectual disabilities and autistic people. However, whether the ABC displays longitudinal measurement invariance (i.e.

View Article and Find Full Text PDF

Objective: Around 30% of people with schizophrenia are refractory to antipsychotic treatment (treatment-resistant schizophrenia). Abnormal structural neuroimaging findings, in particular volume and thickness reductions, are often described in schizophrenia. Novel biomarkers of active brain pathology such as neurofilament light chain protein are now expected to improve current understanding of psychiatric disorders, including schizophrenia.

View Article and Find Full Text PDF

Effect of transcutaneous vagus nerve stimulation in hemodialysis patients: A randomized controlled trial.

Ther Apher Dial

January 2025

Department of Nephrology, The Third Clinical Medical College of China Three Gorges University, Sinopharm Gezhouba Central Hospital, Yichang, China.

Introduction: Transcutaneous auricular vagus nerve stimulation (tVNS) has shown potential in neurological, autoimmune, and cardiovascular disorders, but its effects on HD patients remain unclear. This study aimed to evaluate the efficacy and safety of tVNS in HD patients.

Methods: We conducted a randomized controlled clinical trial on patients receiving HD ≥6 months.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!